Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study-Reference-Cited by-同舟云学术

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Published:2020-03 Issue:3 Volume:7 Page:e226-e237
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kiladjian Jean-Jacques,Zachee Pierre,Hino Masayuki,Pane Fabrizio,Masszi Tamas,Harrison Claire N,Mesa Ruben,Miller Carole B,Passamonti Francesco,Durrant Simon,Griesshammer Martin,Kirito Keita,Besses Carlos,Moiraghi Beatriz,Rumi Elisa,Rosti Vittorio,Blau Igor Wolfgang,Francillard Nathalie,Dong Tuochuan,Wroclawska Monika,Vannucchi Alessandro M,Verstovsek Srdan

Publisher

Elsevier BV

Subject

Hematology

Reference20 articles.

1. Myeloproliferative neoplasms;Spivak;N Engl J Med,2017

2. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study;Tefferi;Leukemia,2013

3. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease;Geyer;J Clin Oncol,2016

4. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera;Marchioli;J Clin Oncol,2005

5. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia;Passamonti;Am J Med,2004

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

3. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

4. Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice;Journal of Clinical Medicine;2024-06-10

5. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia;American Journal of Hematology;2024-06-06